1 week Ago By ABMN Staff
Paragon Financial Partners Inc. reduced its position in shares of Johnson & Johnson ( NYSE:JNJ – Free Report ) by 53.1% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission.
The institutional investor owned 1,977 shares of the company’s stock after selling 2,236 shares during the quarter. Paragon Financial Partners Inc.’s holdings in Johnson & Johnson were worth $286,000 as of its most recent SEC filing.
A number of other institutional investors have also recently modified their holdings of the business. Vinva Investment Management Ltd increased its position in shares of Johnson & Johnson by 6.8% in the third quarter.
Vinva Investment Management Ltd now owns 111,448 shares of the company’s stock valued at $17,988,000 after buying an additional 7,110 shares in the last quarter. Financial Counselors Inc. grew its stake in Johnson & Johnson by 5.
3% in the 3rd quarter. Financial Counselors Inc. now owns 185,093 shares of the company’s stock valued at $29,996,000 after acquiring an additional 9,309 shares during the period.
Meridian Investment Counsel Inc. increased its holdings in Johnson & Johnson by 19.6% in the 3rd quarter.
Meridian Investment Counsel Inc. now owns 22,629 shares of the company’s stock worth $3,667,000 after acquiring an additional 3,710 shares in the last quarter. Charles Schwab Investment Management Inc.
raised its position in Johnson & Johnson by 0.6% during the third quarter. Charles Schwab Investment Management Inc.
now owns 17,639,368 shares of the company’s stock worth $2,858,543,000 after acquiring an additional 102,502 shares during the period. Finally, Lord Abbett & CO. LLC purchased a new position in Johnson & Johnson during the third quarter valued at $69,859,000.
69.55% of the stock is currently owned by institutional investors and hedge funds. Insider Buying and Selling In other news, Director Mark A.
Weinberger purchased 1,000 shares of the stock in a transaction dated Thursday, December 12th. The stock was acquired at an average cost of $147.22 per share, for a total transaction of $147,220.
00. Following the completion of the transaction, the director now directly owns 1,000 shares in the company, valued at approximately $147,220. This represents a ∞ increase in their position.
The purchase was disclosed in a legal filing with the SEC, which is available at this link . 0.16% of the stock is currently owned by corporate insiders.
Analyst Upgrades and Downgrades Get Our Latest Analysis on Johnson & Johnson Johnson & Johnson Trading Up 0.1 % Shares of Johnson & Johnson stock opened at $146.76 on Friday.
The stock has a 50 day moving average of $147.85 and a 200 day moving average of $155.99.
The company has a debt-to-equity ratio of 0.45, a quick ratio of 0.79 and a current ratio of 1.
03. The firm has a market capitalization of $353.34 billion, a price-to-earnings ratio of 22.
07, a PEG ratio of 2.45 and a beta of 0.51.
Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $168.85.
Johnson & Johnson ( NYSE:JNJ – Get Free Report ) last issued its quarterly earnings data on Wednesday, January 22nd. The company reported $2.04 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.
99 by $0.05. The firm had revenue of $22.
52 billion during the quarter, compared to the consensus estimate of $22,438,500 billion. Johnson & Johnson had a return on equity of 34.35% and a net margin of 18.
20%. The company’s quarterly revenue was up 5.3% on a year-over-year basis.
During the same period last year, the company earned $2.29 EPS. As a group, research analysts predict that Johnson & Johnson will post 10.
56 earnings per share for the current year. Johnson & Johnson Dividend Announcement The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Stockholders of record on Tuesday, February 18th will be issued a $1.
24 dividend. The ex-dividend date of this dividend is Tuesday, February 18th. This represents a $4.
96 annualized dividend and a dividend yield of 3.38%. Johnson & Johnson’s dividend payout ratio is currently 74.
59%. Johnson & Johnson Profile ( Free Report ) Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments.
The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. See Also Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson ( NYSE:JNJ – Free Report ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter ..
